Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lowe's

It's likely that these two stocks will continue increasing their dividend payments for the foreseeable future.

2 High-Yielding Dividend Stocks That Just Raised Their Payouts Again

Icecure Medical Ltd

Shanghai Medtronic to exclusively distribute IceSense3 cryoablation systems with a minimum purchase target of $3.5 million in the first 3 years of the contract   First IceSense3 systems to be delivered in 2022 CAESAREA, Israel , June 13, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System (marketed under the brand name IceSense3 in China), that destroys tumors by freezing as an alternative to surgical tumor removal today announced that its wholly-owned subsidiary, IceCure (Shanghai) MedTech Co., Ltd.

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China

Medtronic has been a stable growth company for several decades. Leadership position in cardiovascular, neuroscience, and spine markets will persist into the future.

Medtronic: Stable Growth Ahead

Medtronic's revenue of $8.1 billion was down 1% y-o-y and fell short of the $8.4 billion consensus estimate.

Will Medtronic Stock See Higher Levels?

Medtronic ( MDT , Financial) is one of the world's largest medical device companies. The company develops and manufactures therapeutic medical devices for chronic diseases such as pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy and surgical tools.

Medtronic: A Quality Medical Device Company Facing Pressures

Shares of medical device company Medtronic PLC ( MDT , Financial) have fallen 8% year to date, but are down 23% over the last year.

Why Medtronic Is a Long-Term Winner

Diageo

Lockheed Martin

McCormick

NIKE

Texas Instruments

Exxon Mobil

Recent market volatility has exposed risks at many former high-fliers. But these safe retirement stocks are resistant to the current troubles.

7 Safe Retirement Stocks to Buy So You Can Sleep at Night

AvalonBay Communities

Hudson Pacific Properties

J. M. Smucker

Stryker

Following the holiday weekend, U.S. equities began the shortened trading week lower on the first two trading days. Commentary from JPM's Jamie Dimon and the release of new economic data moved indexes higher and lower throughout the week.

5 Laggards For The Week Ending June 3, 2022

Stanley Black & Decker

AMERCO

With the S&P 500 down 13.95% year to date, value investors are wondering whether it is time to go bargain-hunting.

3 Guru Favorites Trading Near 52-Week Lows

3 Popular Stocks Trading Near 52-Week Lows

General Electric

CHICAGO & DUBLIN--(BUSINESS WIRE)--Clinicians now have added ability to personalize care with the integration of two continuous monitoring solutions from Medtronic plc (NYSE: MDT) – Microstream™ capnography (CO2) and INVOS™ regional oximetry (rSO2) technology for perioperative and ICU care on the GE Healthcare (NYSE: GE) CARESCAPE precision monitoring platform. FDA clearance and CE Mark approval of the integration of these latest technologies on the CARESCAPE platform completes the full suite o

GE Healthcare, Medtronic Partnership Accelerates Global Access to Personalized Care by Delivering Advanced Patient Monitoring Solutions on the CARESCAPE Platform

Medtronic stock is down 6% since the medical device company reported earnings on May 26, 2022. In this article, we'll take a look at MDT stock so you can decide if it deserves a place on your recovery watchlist

Should Medtronic Make the Cut For Your Recovery Watchlist?

Medtronic plc (NYSE: MDT) shares have weakened more than 4% after the company reported weaker than expected fourth-quarter results. The company missed estimates with Q4 EPS and Q4 revenue, and the research company Needham downgraded Medtronic from buy to hold.

Should I buy Medtronic shares in June 2022?

NewCo is expected to operate successfully, leveraging Medtronic's (MDT) capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider.

Medtronic's (MDT) New JV With DaVita to Expand Renal Care Line

Kraft Heinz

Some companies failed to join in on gains of as much as 3% for major indexes.

2 Blue Chip Stocks That Missed Thursday's Big Rally

Medtronic plc (NYSE:MDT ) Q4 2022 Earnings Conference Call May 26, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Head of IR Geoff Martha - CEO Karen Parkhill - CFO Brad Lerman - SVP, General Counsel, Corporate Secretary Bob White - EVP and President of the Medical Surgical Portfolio Sean Salmon - EVP and President of the Cardiovascular Portfolio and former Head of the Diabetes Operating Unit Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Merrill Lynch Larry Biegelsen - Wells Fargo Shagun Singh - RBC Capital Markets Josh Jennings - Cowen Joanne Wuensch - Citi Pito Chickering - Deutsche Bank Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations.

Medtronic plc (MDT) CEO Geoff Martha on Q4 2022 Results - Earnings Call Transcript

On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.

Medtronic's (MDT) Q4 Earnings and Revenues Lag Estimates

DaVita

Medtronic plc (NYSE: MDT) and DaVita Inc (NYSE: DVA) intend to form a new, independent kidney care-focused medical device company (NewCo). NewCo will focus on developing a broad suite of novel kidney care products and solutions, including future home-based products.

Medtronic, DaVita To Jointly Form Kidney Health-Focused Company

Medtronic (MDT) delivered earnings and revenue surprises of -2.56% and 3.85%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q4 Earnings and Revenues Lag Estimates

Medtronic Plc's (NYSE: MDT) Q4 FY22 sales of $8.09 billion decreased 1% Y/Y on a reported basis but increased 1% organically, missing the consensus of $8.42 billion. The company has forecasted Q4 organic revenue growth of approximately 5.5%.

Why Are Medtronic Shares Plunging Today?

The medical-device maker has had a stutter-step recovery from the impact of the Covid-19 pandemic.

Citing Supply-Chain Impact, Medtronic Misses Guidance

Shares of Medtronic PLC PLC, -0.31% dropped 3.2% in premarket trading Thursday, after the medical technology company missed fiscal fourth-quarter profit and sales expectations and provided a downbeat earnings outlook, citing pressure from inflation, supply chain constraints and COVID-19 controls in China. Net income rose to $1.49 billion, or $1.10 a share, from $1.36 billion, or $1.00 a share, in the year-ago period.

Medtronic stock falls after earnings miss and downbeat outlook, but dividend boosted

Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN , May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2022, which ended April 29, 2022. Key Highlights FY22 revenue increased 5% reported and organic FY22 GAAP diluted EPS increased 40%; non-GAAP diluted EPS increased 26% FY22 cash flow from operations of $7.3 billion increased 18%; FY22 free cash flow of $6.0 billion increased 22% Quarterly dividend increased to $0.68, annual $2.72 from prior $2.52; 45th consecutive year of dividend increases Q4 revenue of $8.1 billion decreased 1% reported and increased 1% organic Q4 GAAP diluted EPS of $1.10 increased 10%; non-GAAP diluted EPS of $1.52 increased 2% Company issues FY23 guidance Fiscal year 2022 revenue of $31.686 billion increased 5% as reported and organic, which excludes the $75 million negative impact of foreign currency translation.

Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase

Companies join forces to accelerate kidney care device innovation and improve patient outcomes DUBLIN and DENVER, May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) and DaVita Inc. (NYSE:DVA) today announced the intent to form a new, independent kidney care-focused medical device company ("NewCo" or "the Company") to enhance the patient treatment experience and improve overall outcomes. By bringing together Medtronic's capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider, NewCo will be uniquely positioned to advance the development of differentiated therapies for patients with kidney failure.

Medtronic and DaVita announce new kidney health technology company

Medtronic (NYSE: MDT) is scheduled to report its fiscal fourth-quarter results on Thursday, May 26.

News for Medtronic Stock (MDT)